while persuing my BBA(H), i have done project on financial research of Ranbaxy Laboratories Limited, the main subject of my project is to show the effects of leverage in deceision making.
Shriji Polymers is an ISO 9001:2008, ISO 15378:2011 & CE marking certified Pharma packaging company. Shriji’s comprehensive portfolio of products includes HDPE bottles, PP closures, dosage dispensers & specialty products for pharmaceutical applications.
Shriji combines its technical expertise with innovation to deliver solutions that meet customer’s satisfaction.
Shriji has a huge infrastructure spreading over various locations. It has three existing manufacturing units one each in Ujjain, Pithampur and Goa.
“A study on customer feedback and upgradation of Haem up vet launched or intr...Vatsal Patel
A summer internship project on “A study on customer feedback and upgradation of Haem up vet launched or introduced by cadila pharmaceutical as per market needs”
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Navjyoti Analytics & Research Laboratory - PresentationNavjyotiCommodity
Navjyoti Analytics and Research Laboratory, is an NABL accredited state-of-art food, water, pharma, oil and environment testing Laboratory at Ahmedabad. It's a modern facility set-up in 2017 with latest and best-in-class equipment’s and technology.
It's a Navjyoti Commodity Management Service Ltd's venture. ‘Navjyoti’ is an Agri supply chain service Company. We provide supply chain solutions for Agri commodities such as grains, cereals, pulses, beans, oilseeds and other commercial crops including storage, preservation, quality monitoring, testing and assaying, logistics besides others. We have a pan India presence with over 350 warehouses in operation. Amongst our operational warehouses, we are also working in company developed state of art modern & scientifically designed Agri Logistics Parks (ALP). Our ALPs are designed and developed with an aim to provide a common platform to the various stakeholders across the value chain along with all supporting infrastructures in rural India.
‘Navjyoti’ is a part of century old LN Bangur (LNB) Group of Companies. The group has active interests in Textiles, Tea, Renewable Energy, Financial Services, Health and Wellness, Agriculture, Warehousing and Real Estate.
Vishal Meswani is a business head with over 20 years of experience in the pharmaceutical industry. He has a track record of establishing new business verticals at Lupin Ltd., growing revenues from INR 300 Cr to over INR 3,000 Cr. Currently he heads the Ophthalmology division and previously led the successful Pinnacle Cardiology division, developing strategies to launch new products and brands.
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Group No. 4 set a vision in 2007 to achieve $1 billion in sales, dubbed the "Healthy Billion." In fiscal year 2010-2011, they crossed the $1 billion mark, achieving their goal. They now aspire to reach $3 billion in sales by 2015. The company maintained strong growth across its business segments including India formulations, international formulations, API and intermediates, animal health, and wellness. New product launches and geographic expansions contributed to the financial success.
Shriji Polymers is an ISO 9001:2008, ISO 15378:2011 & CE marking certified Pharma packaging company. Shriji’s comprehensive portfolio of products includes HDPE bottles, PP closures, dosage dispensers & specialty products for pharmaceutical applications.
Shriji combines its technical expertise with innovation to deliver solutions that meet customer’s satisfaction.
Shriji has a huge infrastructure spreading over various locations. It has three existing manufacturing units one each in Ujjain, Pithampur and Goa.
“A study on customer feedback and upgradation of Haem up vet launched or intr...Vatsal Patel
A summer internship project on “A study on customer feedback and upgradation of Haem up vet launched or introduced by cadila pharmaceutical as per market needs”
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Navjyoti Analytics & Research Laboratory - PresentationNavjyotiCommodity
Navjyoti Analytics and Research Laboratory, is an NABL accredited state-of-art food, water, pharma, oil and environment testing Laboratory at Ahmedabad. It's a modern facility set-up in 2017 with latest and best-in-class equipment’s and technology.
It's a Navjyoti Commodity Management Service Ltd's venture. ‘Navjyoti’ is an Agri supply chain service Company. We provide supply chain solutions for Agri commodities such as grains, cereals, pulses, beans, oilseeds and other commercial crops including storage, preservation, quality monitoring, testing and assaying, logistics besides others. We have a pan India presence with over 350 warehouses in operation. Amongst our operational warehouses, we are also working in company developed state of art modern & scientifically designed Agri Logistics Parks (ALP). Our ALPs are designed and developed with an aim to provide a common platform to the various stakeholders across the value chain along with all supporting infrastructures in rural India.
‘Navjyoti’ is a part of century old LN Bangur (LNB) Group of Companies. The group has active interests in Textiles, Tea, Renewable Energy, Financial Services, Health and Wellness, Agriculture, Warehousing and Real Estate.
Vishal Meswani is a business head with over 20 years of experience in the pharmaceutical industry. He has a track record of establishing new business verticals at Lupin Ltd., growing revenues from INR 300 Cr to over INR 3,000 Cr. Currently he heads the Ophthalmology division and previously led the successful Pinnacle Cardiology division, developing strategies to launch new products and brands.
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Group No. 4 set a vision in 2007 to achieve $1 billion in sales, dubbed the "Healthy Billion." In fiscal year 2010-2011, they crossed the $1 billion mark, achieving their goal. They now aspire to reach $3 billion in sales by 2015. The company maintained strong growth across its business segments including India formulations, international formulations, API and intermediates, animal health, and wellness. New product launches and geographic expansions contributed to the financial success.
This document provides an overview of the finance department of Treffer Pharmaceuticals. It discusses the organizational structure of the finance department, the department's role in financial planning, capital structure, cash management, and ratio analysis. It also outlines the finance department's relationships with other departments like marketing, accounting, production, and personnel. The document discusses the sources of funds for the company, its cost control systems, and accounting policies around depreciation and investments.
SMS Pharmaceuticals is an integrated pharmaceutical company focused on API manufacturing with a presence in over 70 countries. The report provides an equity research analysis on SMS Pharmaceuticals with a target price of Rs. 1100 based on a 18-24 month timeframe. Key details include SMS Pharma's financial performance over the last 6 quarters, expected future earnings, peer comparison, and risks. The report recommends SMS Pharma given its robust product portfolio, largest producer of anti-ulcer products, manufacturing facilities approved by USFDA and European authorities, and plans to invest in expanding facilities in Andhra Pradesh.
Financial statement analysis and interpretationstSupa Buoy
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
This is the report of my first Summer training in BBA at Lupin, Ankleshwar plant. This whole report is prepared by me with the help of information provided by the company. Production, Dispatch, Store-warehouse, Purchase, Financial, HR departments are included in this project.
This project also include a Mini Project on "Job Satisfaction". I complete this project with the help of Random Survey method. I hop this report will help you in your study.
For any kind of query or correction in the project contact me through
email- rajat.gandhi27@gmail.com
facebook- www.facebook.com/rajat.gandhi28
Promoted by Mr. Venkat Jasti, Suven is one of the very few companies in India focused on new drug discovery on its own and in partnership with several innovator companies.
The Hyderabad based company basically focuses on CRAMS (contract research and manufacturing services) and assists global innovators in drug development by supplying intermediates for relevant new chemical entities (NCEs) during the clinical phase of drug development. The projects undertaken by the Company include process research, custom synthesis and intermediate manufacturing.
We are looking at Suven from long term investment perspective as drug discovery in itself is a very long cycle. As explained in the business section below, we believe movement of only few projects of the company to higher phases or to commercialization phase can result in substantial increase in sales of the company. Also, while new drug discovery has very low probability of success, more so in the case of CNS, we believe there can be good upside if the company’s SUVN-502 is able to successfully move to Phase III of clinical trials
This document provides a history of the Indian pharmaceutical industry. It discusses how the industry grew after economic liberalization in the 1990s allowed Indian companies to enter generic drug manufacturing. It overtook the market share of multinational companies. The industry is now the 3rd largest producer globally by volume. It discusses the key players, regulations around patents, growth of exports, and challenges around research and development. It also provides an overview of the biotech sector in India and how it is growing but still smaller than the pharmaceutical industry.
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
Dai Ichi Karkaria: Buy at CMP and add on declinesIndiaNotes.com
At CMP of Rs 85, the company is trading at 6.1x its FY14 Adjusted EPS of Rs 13.9. Investors could buy the stock at the CMP and add on dips to Rs.70-76 band (~5.25 xFY14 EPS) for sequential target prices of Rs 111 and 125.
Syngene International Ltd is bringing an IPO at a price band of Rs. 240-250 per share. The IPO aims to achieve listing benefits and raise funds for selling shareholder Biocon Ltd. Syngene is one of India's leading contract research organizations offering integrated drug discovery and development services. It has over 2,100 scientists and facilities across 900,000 square feet. Syngene services 221 clients including 8 of the top 10 pharmaceutical companies and has long-term relationships with multinational companies through dedicated research centers. The IPO appears attractively priced considering Syngene's client base, growth opportunities in the CRO industry, and world-class infrastructure.
Project Report_Pinaki Roy_PGDPM_2013_15_2012004299Pinaki Roy
This document is a project report submitted in partial fulfillment of a Post Graduate Diploma in Project Management. The report details a project conducted at Austin Paints & Chemicals Private Limited in Kolkata, India to implement systematic analysis, monitoring, and control for improved productivity and performance. The report includes sections on the organizational profile, research objectives and scope, methodology, data analysis and presentation, conclusions, and suggestions. It aims to familiarize small and medium enterprises with universally accepted management techniques that can be adopted in key functional areas like finance, supply chain, and marketing.
Dynemic Products is India’s leading manufacturer and exporter of complete range of Food colours, Lake colours, Blended colours, & US-FDA certified FD&C colours & Dye Intermediates.
The document provides details about the author's internship at Jubilant Life Sciences. It discusses:
1) The author's responsibilities in controlling machines like pumps, boilers, and compressors to regulate mass flow rates, temperatures, and pressures.
2) A challenging situation where boiler furnace temperature increased drastically due to high coal mass flow, which was solved by shutting down some nozzles.
3) Maintenance tasks performed on equipment like testing and maintaining a heat exchanger, setting up a new refrigeration system, and replacing compressor parts.
This document is a report submitted by Husain Fairoz B Bahamani to Karnataka University as part of a summer internship project conducted at Hindustan Petroleum Corporation Limited (HPCL) in Belgaum to analyze customer satisfaction towards HPCL's Drive Track Plus program. The report includes an introduction to HPCL, details of the internship project such as objectives and methodology, findings from the analysis, and conclusions. It was submitted in partial fulfillment of an MBA degree and includes certificates from HPCL and the university.
Singapore provides key advantages for life sciences companies, including being the easiest place to do business, excellent connectivity, access to talent, and an intellectual property friendly environment. It has established capabilities in areas like pharmaceutical and biologics manufacturing, drug discovery and development, and clinical research. Over 50 biomedical sciences companies and 30 research institutes are located in Singapore, driving innovation.
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
This document provides an overview of Dr. Reddy's Laboratories, a pharmaceutical company based in India. It discusses the company's commitment to innovation and providing affordable medicines globally. It summarizes Dr. Reddy's operations across generic medicines, active pharmaceutical ingredients, proprietary products including new drug development, and key markets and partnerships around the world. The company aims to address unmet medical needs through scientific research and help make medicines more accessible.
The document analyzes the degree of operating leverage of Bharti Airtel Ltd, an Indian telecommunications company that operates in 19 countries. It provides the formula used to calculate degree of operating leverage. The analysis finds that Bharti Airtel had a high degree of operating leverage in 2006 of 2.6251, but it decreased in subsequent years as the company efficiently utilized its fixed operating costs to increase sales volume and profits.
Bharti Airtel is an Indian multinational telecommunications services company headquartered in New Delhi, India. It operates in 18 countries across South Asia and Africa. Bharti Airtel was founded in 1995 and provides mobile telephony, broadband and fixed-line services to over 400 million customers. The company is led by Chairman and Managing Director Sunil Bharti Mittal and had annual revenues of $14 billion in 2016.
Wipro is an Indian multinational IT consulting and system integration services company headquartered in Bangalore, India. It was founded in 1945 as a manufacturer of vegetable oils but later transitioned to IT services. Wipro is now one of India's largest publicly traded companies and the seventh largest IT services firm worldwide, with over $8 billion in revenue. The company has over 1.5 lakh employees serving clients in over 60 countries. While initially focused on software services and BPO, Wipro has diversified into several other sectors like consumer care, lighting, healthcare and infrastructure engineering through spin-offs.
This document provides an overview of the finance department of Treffer Pharmaceuticals. It discusses the organizational structure of the finance department, the department's role in financial planning, capital structure, cash management, and ratio analysis. It also outlines the finance department's relationships with other departments like marketing, accounting, production, and personnel. The document discusses the sources of funds for the company, its cost control systems, and accounting policies around depreciation and investments.
SMS Pharmaceuticals is an integrated pharmaceutical company focused on API manufacturing with a presence in over 70 countries. The report provides an equity research analysis on SMS Pharmaceuticals with a target price of Rs. 1100 based on a 18-24 month timeframe. Key details include SMS Pharma's financial performance over the last 6 quarters, expected future earnings, peer comparison, and risks. The report recommends SMS Pharma given its robust product portfolio, largest producer of anti-ulcer products, manufacturing facilities approved by USFDA and European authorities, and plans to invest in expanding facilities in Andhra Pradesh.
Financial statement analysis and interpretationstSupa Buoy
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
This is the report of my first Summer training in BBA at Lupin, Ankleshwar plant. This whole report is prepared by me with the help of information provided by the company. Production, Dispatch, Store-warehouse, Purchase, Financial, HR departments are included in this project.
This project also include a Mini Project on "Job Satisfaction". I complete this project with the help of Random Survey method. I hop this report will help you in your study.
For any kind of query or correction in the project contact me through
email- rajat.gandhi27@gmail.com
facebook- www.facebook.com/rajat.gandhi28
Promoted by Mr. Venkat Jasti, Suven is one of the very few companies in India focused on new drug discovery on its own and in partnership with several innovator companies.
The Hyderabad based company basically focuses on CRAMS (contract research and manufacturing services) and assists global innovators in drug development by supplying intermediates for relevant new chemical entities (NCEs) during the clinical phase of drug development. The projects undertaken by the Company include process research, custom synthesis and intermediate manufacturing.
We are looking at Suven from long term investment perspective as drug discovery in itself is a very long cycle. As explained in the business section below, we believe movement of only few projects of the company to higher phases or to commercialization phase can result in substantial increase in sales of the company. Also, while new drug discovery has very low probability of success, more so in the case of CNS, we believe there can be good upside if the company’s SUVN-502 is able to successfully move to Phase III of clinical trials
This document provides a history of the Indian pharmaceutical industry. It discusses how the industry grew after economic liberalization in the 1990s allowed Indian companies to enter generic drug manufacturing. It overtook the market share of multinational companies. The industry is now the 3rd largest producer globally by volume. It discusses the key players, regulations around patents, growth of exports, and challenges around research and development. It also provides an overview of the biotech sector in India and how it is growing but still smaller than the pharmaceutical industry.
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
Dai Ichi Karkaria: Buy at CMP and add on declinesIndiaNotes.com
At CMP of Rs 85, the company is trading at 6.1x its FY14 Adjusted EPS of Rs 13.9. Investors could buy the stock at the CMP and add on dips to Rs.70-76 band (~5.25 xFY14 EPS) for sequential target prices of Rs 111 and 125.
Syngene International Ltd is bringing an IPO at a price band of Rs. 240-250 per share. The IPO aims to achieve listing benefits and raise funds for selling shareholder Biocon Ltd. Syngene is one of India's leading contract research organizations offering integrated drug discovery and development services. It has over 2,100 scientists and facilities across 900,000 square feet. Syngene services 221 clients including 8 of the top 10 pharmaceutical companies and has long-term relationships with multinational companies through dedicated research centers. The IPO appears attractively priced considering Syngene's client base, growth opportunities in the CRO industry, and world-class infrastructure.
Project Report_Pinaki Roy_PGDPM_2013_15_2012004299Pinaki Roy
This document is a project report submitted in partial fulfillment of a Post Graduate Diploma in Project Management. The report details a project conducted at Austin Paints & Chemicals Private Limited in Kolkata, India to implement systematic analysis, monitoring, and control for improved productivity and performance. The report includes sections on the organizational profile, research objectives and scope, methodology, data analysis and presentation, conclusions, and suggestions. It aims to familiarize small and medium enterprises with universally accepted management techniques that can be adopted in key functional areas like finance, supply chain, and marketing.
Dynemic Products is India’s leading manufacturer and exporter of complete range of Food colours, Lake colours, Blended colours, & US-FDA certified FD&C colours & Dye Intermediates.
The document provides details about the author's internship at Jubilant Life Sciences. It discusses:
1) The author's responsibilities in controlling machines like pumps, boilers, and compressors to regulate mass flow rates, temperatures, and pressures.
2) A challenging situation where boiler furnace temperature increased drastically due to high coal mass flow, which was solved by shutting down some nozzles.
3) Maintenance tasks performed on equipment like testing and maintaining a heat exchanger, setting up a new refrigeration system, and replacing compressor parts.
This document is a report submitted by Husain Fairoz B Bahamani to Karnataka University as part of a summer internship project conducted at Hindustan Petroleum Corporation Limited (HPCL) in Belgaum to analyze customer satisfaction towards HPCL's Drive Track Plus program. The report includes an introduction to HPCL, details of the internship project such as objectives and methodology, findings from the analysis, and conclusions. It was submitted in partial fulfillment of an MBA degree and includes certificates from HPCL and the university.
Singapore provides key advantages for life sciences companies, including being the easiest place to do business, excellent connectivity, access to talent, and an intellectual property friendly environment. It has established capabilities in areas like pharmaceutical and biologics manufacturing, drug discovery and development, and clinical research. Over 50 biomedical sciences companies and 30 research institutes are located in Singapore, driving innovation.
Global supply chain in ranbaxy paonta sahib manufacturing facilityAnkur Srivastava
This is a project report made by me on the Global Supply Chain Process of Ranbaxy Laboratories Ltd., one of the world's largest Pharmaceutical Manufacturers; and its impact on its Global Business. The related study was done in the year 2011 and report was prepared then.
This document provides an overview of Dr. Reddy's Laboratories, a pharmaceutical company based in India. It discusses the company's commitment to innovation and providing affordable medicines globally. It summarizes Dr. Reddy's operations across generic medicines, active pharmaceutical ingredients, proprietary products including new drug development, and key markets and partnerships around the world. The company aims to address unmet medical needs through scientific research and help make medicines more accessible.
The document analyzes the degree of operating leverage of Bharti Airtel Ltd, an Indian telecommunications company that operates in 19 countries. It provides the formula used to calculate degree of operating leverage. The analysis finds that Bharti Airtel had a high degree of operating leverage in 2006 of 2.6251, but it decreased in subsequent years as the company efficiently utilized its fixed operating costs to increase sales volume and profits.
Bharti Airtel is an Indian multinational telecommunications services company headquartered in New Delhi, India. It operates in 18 countries across South Asia and Africa. Bharti Airtel was founded in 1995 and provides mobile telephony, broadband and fixed-line services to over 400 million customers. The company is led by Chairman and Managing Director Sunil Bharti Mittal and had annual revenues of $14 billion in 2016.
Wipro is an Indian multinational IT consulting and system integration services company headquartered in Bangalore, India. It was founded in 1945 as a manufacturer of vegetable oils but later transitioned to IT services. Wipro is now one of India's largest publicly traded companies and the seventh largest IT services firm worldwide, with over $8 billion in revenue. The company has over 1.5 lakh employees serving clients in over 60 countries. While initially focused on software services and BPO, Wipro has diversified into several other sectors like consumer care, lighting, healthcare and infrastructure engineering through spin-offs.
Case study Analysis and Presentation -ICICI LombardPurvi Jain
ICICI Lombard GIC Ltd is a joint venture between ICICI Bank and Fairfax Financial Holdings. It deals in personal and business insurance products. The document discusses ICICI Lombard's management structure, SWOT analysis, role of insurance in the economy and society, products offered, distribution channels, use of MIS, and potential for growth in the Indian insurance sector.
The document provides an overview of the Indian telecom industry and Bharti Airtel. It discusses the evolution of the telecom sector in India and key milestones. It then introduces Bharti Airtel, covering its financial performance, subsidiaries, organizational structure, marketing strategies, and use of Porter's five forces analysis. The summary analyzes Airtel's growth in subscriber base, revenues, and profits in recent years.
FINANCIAL AND FUNDAMENTAL ANALAYSIS ON ICICI BANKAnkit Jaiswal
The document is a project report submitted by Ankit Jaiswal for the degree of BBA at Sikkim Manipal University. It includes an introduction, student declaration, examiner certification, study centre certificate, and table of contents. The project aims to conduct a financial and fundamental analysis of ICICI Bank over a period of 5 years from 2006-2010. Secondary data will be collected from sources like books, websites, and databases to analyze the economy, industry, and company. Key tools that will be used include ratios, cash flows, valuation techniques, and macroeconomic indicators. The analysis will help evaluate ICICI Bank's performance and identify opportunities and limitations.
Financial Statment Analysis of Icici BankAnil Nandyala
This document provides an analysis of the financial statements of ICICI Bank for the years 2010 and 2011. It summarizes the bank's timeline since 1994. It outlines key points from the Board of Directors' report such as changes in interest rates and loans. It describes significant accounting policies and analyzes ratios related to liquidity, profits, operations, and performance compared to other banks. It also tracks some announcements that impacted the bank's stock price.
HDFC Life and ICICI Prudential : Financial analysis and Portfolio Comparisonkkslideshare77
The document compares HDFC Life and ICICI Prudential Life Insurance through financial analysis and a product comparison. It analyzes the insurers' solvency ratios, operating expenses, assets under management, and unit linked funds. HDFC Life's solvency ratio is above the regulatory requirement of 1.5. The document also compares the insurers' term assurance plan products and portfolios. Key differences and inferences about the companies are presented.
Bharti Airtel is India's largest telecommunications services provider with over 220 million subscribers across its mobile, broadband, and enterprise services. It faces competition from other major players like Reliance, Idea, Vodafone, and public sector providers BSNL and MTNL. Airtel has a 28% market share of India's GSM subscriber base. It has strengths in its nationwide network footprint and strong brand recognition, but also faces threats from new low-cost entrants and market saturation. The document analyzes Airtel's competitive position and provides recommendations around rural marketing, advertising, and product development.
Nike is the largest seller of athletic footwear and apparel in the world. It designs, develops, and sells products under its own brand along with Jordan, Hurley, and Converse. In 2015, Nike had revenues of $33 billion and net income of $3.5 billion. While Nike faces challenges from increased competition and changing consumer spending habits, its strong brand recognition and endorsement deals with star athletes provide opportunities for continued growth.
This document summarizes a strategic analysis of Nike. It outlines Nike's vision, mission, strengths such as its brand awareness and marketing, and weaknesses like social issues. It also analyzes the internal and external environment, including opportunities like growing athletic shoe sales and threats like increased competition. The analysis finds that Nike relies heavily on endorser contracts and needs a more flexible approach to keep up with consumers moving from sports to fashion-oriented sportswear.
The document analyzes various financial ratios for Infosys Technologies Ltd for the financial years 2009 and 2008.
Some key highlights from the ratio analysis include:
1) The company maintained a high liquidity with current ratios of 3.29 in 2009 and 2.10 in 2008. Cash ratios also increased from 4.03 in 2008 to 4.83 in 2009.
2) The company had no debt and sufficient cash flows to meet its strategic objectives and maintain surplus liquidity.
3) Returns on assets marginally decreased from 38.81% in 2008 to 37.83% in 2009 while returns on investment increased from 25.04% to 29.24% over the same period.
Please download the file and view the presentation.
Notes for each of the slides are present in the notes section
(Images used for representational purposes only)
Nike was founded in 1962 and is a major multinational corporation that designs and markets athletic footwear, apparel, and equipment. It has grown significantly over the years through strategic acquisitions and partnerships. Nike faces intense competition from companies like Adidas but maintains competitive advantages through innovative product design and large economies of scale. Going forward, Nike aims to continue growing its global brand and market share while also improving its social and environmental sustainability.
The Coca-Cola Company - Financial Analysis and ProjectionsRaeann Bailey
The Coca-Cola Company is the world's largest beverage company operating in over 200 countries. In 2011, it generated $46.5 billion in net operating revenues and $8.6 billion in net income. The company owns or licenses over 500 beverage brands, including its biggest brands, Coca-Cola, Diet Coke, Fanta and Sprite. It has a large global distribution system and employs over 146,000 people worldwide. In 2010, it acquired Coca-Cola Enterprise's North American business for $12.3 billion to gain additional market share in North America.
Wipro is a global IT services company incorporated in 1945 in India. It provides IT services, software solutions, and research and development services to clients worldwide. Key points:
- In FY2012-13, Wipro achieved revenues of ₹377 billion with 17% year-on-year growth, and net income of ₹61 billion with also 17% growth.
- The IT/ITeS industry is a major driver of India's economy, estimated to contribute 7.5% to GDP and provide millions of jobs.
- A financial analysis of Wipro shows some decline in profitability ratios in recent years, but strong liquidity and financial leverage. Peer comparison finds Wipro
This document analyzes Coca-Cola's financial statements and business strategies. It begins with an analysis of Coca-Cola's governance, including details about the CEO, board of directors, and executive compensation. It then discusses Porter's Five Forces analysis of the soda industry, finding rivalry to be high but threats of new entrants and substitutes to be medium. The document also analyzes Coca-Cola's income statements, balance sheets, profitability, and forecasts growth.
This document is a corporate financial analysis report on Bharti Airtel that was submitted by a group of students. It begins with an introduction to the telecommunications industry in India, outlining key milestones such as the establishment of telephone services in 1881 and the opening of the market to competition in 1996. It then discusses the current state of the fast-growing Indian telecom sector and some of the major players, including Bharti Airtel. The objective of the report is to analyze Bharti Airtel's financial statements over the last three years and compare its performance to industry peers.
This document is a 6 week summer training report submitted by Deepika Kumari, a student at Lovely Professional University. The report details her internship at Naxpar Pharma Pvt Ltd in Baddi, Himachal Pradesh from June 1-July 15, 2015. The report includes an introduction to Naxpar Pharma and describes the company's management, vision, objectives, products, and the structure of the finance department. The bulk of the report analyzes working capital management at Naxpar Pharma through comparative statements, cash flow analysis, and trend analysis.
Ranbaxy is India's largest pharmaceutical company, producing generic medicines for over 125 countries. It was founded in 1961 and went public in 1973. Ranbaxy has a global footprint with manufacturing facilities in 8 countries and offices in 43 countries. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, now ranking among the top 20 pharmaceutical companies globally. Ranbaxy's mission is to enrich lives globally with quality and affordable pharmaceuticals.
This document provides an overview of Deepak Mahadev Salunke's summer internship report on Privi Organics Limited located in Mahad. It includes an introduction, objectives of the study, and outlines of various chapters that will discuss the company profile, products/services, department functions, CSR activities, SWOT analysis, and conclusions. The report was submitted to Prof. Saumyabrata Nath of S.A.V. Acharya Institute of Management Studies to partially fulfill the requirements for a Master of Management Studies degree.
PRAN is a leading food and beverage company in Bangladesh that was founded in 1981. It has grown to become one of the largest and most successful companies in Bangladesh, challenging multinational companies. PRAN produces over 200 products across 10 categories including juices, drinks, mineral water, bakery items, carbonated beverages, snacks, culinary products, confectionery, biscuits and dairy. The company has a mission to alleviate poverty and hunger through employment. It has a large domestic market share in Bangladesh and also exports products to over 80 other countries.
Here is my report on PRAN-RFL group
// TEAM STARK //
- American International University Bangladesh -
Take Idea from this report but do not copy from this ...
This document provides an analysis of Alembic Pharmaceuticals Ltd conducted by two MBA students, Nawaz Gazi and Ashutosh Jha, as a project requirement. It includes an introduction to the company's history and operations, product profiles, research and development activities, and a financial analysis including ratio analysis. Key points covered include Alembic being a leading Indian pharmaceutical company established in 1907 with vertically integrated operations and facilities in Vadodara and Baddi, manufacturing a range of APIs and formulations across several therapeutic areas. The students analyzed the company's financials and conducted ratio analyses to evaluate its performance and position in the industry.
Report : Financial analysis of aanjaneya life careSwapnil Chavan
This document provides a financial analysis report on Aanjaneya Lifecare submitted by Swapnil Chavan and Shreyash Pimparkar. It includes an introduction to the company, certificates of work completion, declarations, preface, acknowledgements, contents, and an overview of the company. The document appears to analyze the financial performance and position of Aanjaneya Lifecare through ratios and annual reports from 2012-2013.
PRAN is the largest food and beverage processing company in Bangladesh. It has strong planning, organizing, leading, and controlling functions in its management. PRAN plans thoroughly with goals, strategies, and short-term targets. It involves employees in planning and allows flexibility. PRAN organizes its production system efficiently with standard processes. It has a clear organizational structure and leadership styles that vary based on employees and situations. PRAN motivates employees through rewards, promotions, and setting examples. It communicates changes well and increases productivity through target-oriented tasks.
The document is a summer internship project report submitted by Rohit Singh about his internship at DS Drinks & Beverages Pvt. Ltd. It discusses the company profile of Dharampal Satyapal Group which owns DS Drinks & Beverages. It covers the group's history, expansion into various business sectors including FMCG, packaging, hospitality, and more. It also discusses the mineral water industry in India, catch beverages' competitors and target markets, and Rohit Singh's research methodology and objectives during the internship.
External environmental analysis of frootoOLIUR RAHMAN
Pran Frooto is a mango juice product launched in Bangladesh in 2007 by PRAN-RFL Group, one of the largest conglomerates in Bangladesh. As the leader in the juice category market, Frooto has become very popular among consumers for its unique taste and packaging. However, it faces competition from other juice brands such as Frutika, Shezan, Mangolee, and Tropicana. As the oldest brand in the market, PRAN and its Frooto product have strong brand recognition and supply chain, but must continue innovating and competing on quality, price, and marketing to maintain their market position against growing competitors.
Kishan Kumar completed a summer internship project at Ranbaxy Laboratories Limited to study the market potential of multi-vitamins and the antibiotic cefexime. The project involved two tasks - understanding doctors' perceptions when prescribing multi-vitamins and cefexime, and analyzing the market potential of these products when sold over-the-counter versus through prescriptions. Kumar conducted surveys of doctors and retailers to gather data for the analysis. The goal of the project was to help Ranbaxy better understand opportunities in these therapeutic areas.
The document provides an overview of Ranbaxy Laboratories Ltd's project report on studying the working capital management of the company. It includes an introduction stating the importance of working capital management. It then discusses the pharmaceutical industry profile in India and Ranbaxy's research and development activities. The remainder of the report appears to analyze Ranbaxy's financial performance and working capital management through various ratios and comparisons to its competitors and industry standards.
Pharmaceutical is a booming sector in the country today. Foreign investments have flowed into the country over the past few years in huge amounts. Bangladesh, with a population base of 160m provides a very prospective environment for foreign Pharmaceutical to invest. Who are increasingly becoming more capable of purchasing consumer goods, and this class is growing says a study by World Bank.
The Company started its operations as Pfizer (Bangladesh) Limited in 1972. For the next two decades it continued as a highly successful subsidiary of Pfizer Corporation. However, by the late 1990s the focus of Pfizer had shifted from formulations to research. In accordance with this transformation, Pfizer divested its interests in many countries, including Bangladesh. Specifically, in 1993 Pfizer transferred the ownership of its Bangladesh operations to local shareholders, and the name of the company was changed to Renata Limited.
In this report, we have tried to find out how Renata Limited maintains its Financial Accounting policies and develops its businesses in this one of the most competitive Pharmaceutical markets in the world. ACI Ltd, Beximco Pharmaceuticals Ltd, Essential Drugs Company Ltd, Square Pharmaceuticals Ltd etc are competitors of Pharmaceutical markets. The objective of this assignment is to begin to integrate the many concepts we have studied and to give an opportunity to apply our financial accounting in a real-world setting. Renata Limited performs this hard job through applying our studied strategies. Renata Limited is earning Goodwill and Customer Satisfaction through providing quality services and maintaining up-to-date business strategies. And after analyzing the reports and studying the market it is quite clear that they are fairing quite well according to their company objectives.
Dr. Reddy's Laboratories provided an investor presentation at the Jefferies Global Healthcare Conference in 2016. The presentation contained 3 key sections:
1. An executive summary that outlined Dr. Reddy's strong financial performance over the past decade and optimistic future outlook driven by investments in proprietary products, biologics, and Aurigene.
2. A company overview section that described Dr. Reddy's integrated business model across global generics, pharmaceutical services and active ingredients, and proprietary products. It highlighted the company's industry-leading product development skills and vertically integrated infrastructure.
3. FY17 priorities that focused on accelerating growth in biologics and proprietary products, improving R&D productivity, strengthening
Renata Ltd is one of the top pharmaceutical companies in Bangladesh. To evaluate Renata's financial performance and condition from 2010-2014, various liquidity ratios were analyzed. The current ratio fluctuated over the years, decreasing in 2011 and 2013 but increasing in 2012 and 2014. The quick ratio followed a similar trend. The average collection period and days inventory outstanding generally increased over the years, indicating slower collection of receivables and higher inventory levels being held. The accounts receivable and inventory turnover ratios decreased in most years, suggesting slower turnover of these current assets.
Opportunity and threats of pran Frooto_through six questionsOLIUR RAHMAN
Opportunities and Threats through six question in Strategic management.The Six questions are;
1.How strong are the industry’s competitive forces?
2.What are the driving forces in the industry, and what impact will they have on competitive intensity and industry profitability?
3.What market positions do industry rivals occupy—who is strongly positioned and who is not?
4.What strategic moves are rivals likely to make next?
5.What are the industry’s key success factors?
6.Is the industry outlook conducive to good profitability?
Retention of employees @ pharmaceutical industry project report mba marktingBabasab Patil
The document discusses retention of employees in the pharmaceutical industry. It begins with an introduction to Lake Chemicals, a pharmaceutical company located in Bangalore, India. It then provides background on Lake Chemicals, including its vision, facilities, products, and organizational profile. Next, it discusses the objectives, methodology, findings, and suggestions of a research project on employee satisfaction and retention at Lake Chemicals. It concludes that employee performance is positively correlated with organizational performance at Lake Chemicals.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
The document is a resume for Ankur Singh summarizing his professional experience and qualifications. It details his 8 years of experience in strategic planning, business development, and project management roles at various companies including Jubilant Life Sciences Limited, SRF Limited, GMR Group, and Panacea Biotec Limited. It also lists his educational background which includes an MBA from the Indian Institute of Finance and a BSc in Biology. The resume demonstrates Ankur Singh's expertise in areas such as strategy formulation, financial analysis, mergers and acquisitions, and business opportunity evaluation.
CRYOBANKS REPORT STEM CELL AWARENESS IN PUNETanya Bhalla
This document provides an overview of Cryobanks International India, a stem cell banking company. It discusses the company's management team and various products and services offered. Key points include:
- Cryobanks International India is a joint venture that provides umbilical cord blood stem cell processing and storage.
- The company follows international standards and certifications to ensure high quality processing and storage.
- It has expanded operations to several countries in Asia and Africa through joint ventures.
- Products include private and public stem cell banking from umbilical cord blood as well as stem cell banking from cord tissue.
- The stem cell industry is projected to grow significantly in coming years based on potential medical applications
South Dakota State University degree offer diploma Transcriptynfqplhm
办理美国SDSU毕业证书制作南达科他州立大学假文凭定制Q微168899991做SDSU留信网教留服认证海牙认证改SDSU成绩单GPA做SDSU假学位证假文凭高仿毕业证GRE代考如何申请南达科他州立大学South Dakota State University degree offer diploma Transcript
Discover the Future of Dogecoin with Our Comprehensive Guidance36 Crypto
Learn in-depth about Dogecoin's trajectory and stay informed with 36crypto's essential and up-to-date information about the crypto space.
Our presentation delves into Dogecoin's potential future, exploring whether it's destined to skyrocket to the moon or face a downward spiral. In addition, it highlights invaluable insights. Don't miss out on this opportunity to enhance your crypto understanding!
https://36crypto.com/the-future-of-dogecoin-how-high-can-this-cryptocurrency-reach/
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
How to Identify the Best Crypto to Buy Now in 2024.pdfKezex (KZX)
To identify the best crypto to buy in 2024, analyze market trends, assess the project's fundamentals, review the development team and community, monitor adoption rates, and evaluate risk tolerance. Stay updated with news, regulatory changes, and expert opinions to make informed decisions.
Fabular Frames and the Four Ratio ProblemMajid Iqbal
Digital, interactive art showing the struggle of a society in providing for its present population while also saving planetary resources for future generations. Spread across several frames, the art is actually the rendering of real and speculative data. The stereographic projections change shape in response to prompts and provocations. Visitors interact with the model through speculative statements about how to increase savings across communities, regions, ecosystems and environments. Their fabulations combined with random noise, i.e. factors beyond control, have a dramatic effect on the societal transition. Things get better. Things get worse. The aim is to give visitors a new grasp and feel of the ongoing struggles in democracies around the world.
Stunning art in the small multiples format brings out the spatiotemporal nature of societal transitions, against backdrop issues such as energy, housing, waste, farmland and forest. In each frame we see hopeful and frightful interplays between spending and saving. Problems emerge when one of the two parts of the existential anaglyph rapidly shrinks like Arctic ice, as factors cross thresholds. Ecological wealth and intergenerational equity areFour at stake. Not enough spending could mean economic stress, social unrest and political conflict. Not enough saving and there will be climate breakdown and ‘bankruptcy’. So where does speculative design start and the gambling and betting end? Behind each fabular frame is a four ratio problem. Each ratio reflects the level of sacrifice and self-restraint a society is willing to accept, against promises of prosperity and freedom. Some values seem to stabilise a frame while others cause collapse. Get the ratios right and we can have it all. Get them wrong and things get more desperate.
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
Monthly Market Risk Update: June 2024 [SlideShare]Commonwealth
Markets rallied in May, with all three major U.S. equity indices up for the month, said Sam Millette, director of fixed income, in his latest Market Risk Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
A toxic combination of 15 years of low growth, and four decades of high inequality, has left Britain poorer and falling behind its peers. Productivity growth is weak and public investment is low, while wages today are no higher than they were before the financial crisis. Britain needs a new economic strategy to lift itself out of stagnation.
Scotland is in many ways a microcosm of this challenge. It has become a hub for creative industries, is home to several world-class universities and a thriving community of businesses – strengths that need to be harness and leveraged. But it also has high levels of deprivation, with homelessness reaching a record high and nearly half a million people living in very deep poverty last year. Scotland won’t be truly thriving unless it finds ways to ensure that all its inhabitants benefit from growth and investment. This is the central challenge facing policy makers both in Holyrood and Westminster.
What should a new national economic strategy for Scotland include? What would the pursuit of stronger economic growth mean for local, national and UK-wide policy makers? How will economic change affect the jobs we do, the places we live and the businesses we work for? And what are the prospects for cities like Glasgow, and nations like Scotland, in rising to these challenges?
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
How Poonawalla Fincorp and IndusInd Bank’s Co-Branded RuPay Credit Card Cater...beulahfernandes8
The eLITE RuPay Platinum Credit Card, a strategic collaboration between Poonawalla Fincorp and IndusInd Bank, represents a significant advancement in India's digital financial landscape. Spearheaded by Abhay Bhutada, MD of Poonawalla Fincorp, the card leverages deep customer insights to offer tailored features such as no joining fees, movie ticket offers, and rewards on UPI transactions. IndusInd Bank's solid banking infrastructure and digital integration expertise ensure seamless service delivery in today's fast-paced digital economy. With a focus on meeting the growing demand for digital financial services, the card aims to cater to tech-savvy consumers and differentiate itself through unique features and superior customer service, ultimately poised to make a substantial impact in India's digital financial services space.
1. 1 | P a g e
Shree Agrasain College 2012
FINAL REPORT
Leverage Analysis in Financial Management
OF
RANBAXY LABORATORIES LIMITED
Submitted by-:
RAHUL RAI
Roll No: 434-BBA10M-0008
Reg No: 4341121003809
SHREE AGRASAIN
COLLEGE
2. 2 | P a g e
Shree Agrasain College 2012
Leverage Analysis in Financial Management
OF
USING CAPITAL STRUCTURE & LEVERAGE
By
RAHUL KR. RAI
A Report Submitted in partial fulfillment
of the requirement for the Bachelor of Business Administration
(BBA) Program of
Under the guidance of
Mr. NIBIR GOSWAMI Mr.AMOD GUJRAL
College Guide Company Guide
4. 4 | P a g e
Shree Agrasain College 2012
Acknowledgement
I am profoundly thankful to MR. Amod Gujral, HR. Manager, Ranbaxy
Laboratories Limited, for his cordial treatment and also for his expert guidance
and constant assistant given in the course of this project with a deep sense of
gratitude. It’s my real honor and pleasure, to be associated with Ranbaxy
Laboratories. I deeply express my gratitude to the company for giving me an
opportunity to work as winter trainee at their corporate office under Winter
Internship Program (WIP). Also special thanks to Sr. Prof Nibir Goswami For
special guidance and all the respected teachers of BBA(H) department. Our
also goes to the kind Co-operation of our college library from where we could
collect a vast treasure of knowledge. We would like to thanks the countless
number peoples especially who helped get this work out of door. While
developing this project we had to consult many people from different grounds
of activity. We would like to thank our parents without whom this project
would never have been completed. The kind and ready help and advice
extended by them is greatly acknowledged. We also express our whole hearted
thanks to our friends who criticized and motivated us during the tenure of the
study and to all my elders for the inspiration and encouragement through the
course.
5. 5 | P a g e
Shree Agrasain College 2012
Topics Page No
1. Introduction 6
2. Objective 7
3. Importance 8
4. Methodology 9
5. Company Profile
a. Introduction to Ranbaxy Laboratories Ltd. 10
b. World Wide Operation 12
c. Company Products 13
i. Theoretical Background on Financial Analysis
a. Leverage 15
b. Capital Structure 17
c. CVP Analysis 19
d. EBIT/EPS Analysis 21
ii. Analysis &Interpretation 23
iii. 10 year at a glance 39
6. Recommendations 40
7. Advantages 43
8. Limitations 45
9. Conclusion 46
10. Bibliography 47
11. Attachments 48
6. 6 | P a g e
Shree Agrasain College 2012
Every financial manager is involved in financial decision making and financial
planning in order to take right decision at right time, he should be equipped with
sufficient past and present information about the firm and its operations and how it
is changing overtime. Much of this information that is used by financial manager to
take various decisions and to plan for the future is derived from the financial
statements
For selecting a target debt –equity mix, the firm analyses a number of factors. One
such factor is leverage. The capital structure decision involves a choice between risk
and expected returns. The use of more and more debt capital raises the risk factor of
the firm’s earnings stream but it also tends to provide a higher expected rate of
return to the shareholders. In this chapter, we consider the various aspects of
leverage and risks in planning the capital structure of a firm.
Financial management has assumed greater importance today as the financial
strategies required to survive in the competitive environment have become very
important. In the financial markets also new instruments and concepts are coming
and one must say that a finance manager of today is operating in a more complex
environment. A study of theories and concepts of financial management has therefore
become a part of paramount importance for academics as well as for practitioners
but there are many concepts and theories about which controversies exist as no
unanimous opinion is reached as yet.
The project, Leverage Analysis in Financial Management. further aims at
discussing and understanding the concepts of financial management of Ranbaxy
Laboratories Limited.; the functions expect to be performed by the financial
management as well as the objectives of financial managements
INTRODUCTION
7. 7 | P a g e
Shree Agrasain College 2012
It shows relation between variousa spects-
particularly Risk & Reward
Leverage is a relation of your
efforts and rewards
Some factors like fixed cost resources etc.
have impact on increase or decrease in
profit.
Objective
8. 8 | P a g e
Shree Agrasain College 2012
Leverage is some tool to
help you accelerateyour
speed.
It increases your speed and
also your risk.
It improves returns on
equity.
IMPORTANCE
9. 9 | P a g e
Shree Agrasain College 2012
Personal Interview
Printed and Digital Sources
Questionnaire
METHODOLOGY
10. 10 | P a g e
Shree Agrasain College 2012
Ranbaxy Profile
About Ranbaxy
Profile
Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated,
research based, international pharmaceutical company, producing a wide range of quality, affordable
generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today
has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global
footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over
125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies,
Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The
combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational
deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global
reach and in its capabilities in drug development and manufacturing.
Ranbaxy was incorporated in 1961 and went public in 1973.
Mission
Ranbaxy's mission is 'Enriching lives globally, with quality and affordable pharmaceuticals'.
Financials
For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix
of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011,
North America, the Company's largest market contributed sales of US $ 791 Mn, Europe contributing US
$ 297 Mn and Asia clocking sales of US $ 503 Mn.
11. 11 | P a g e
Shree Agrasain College 2012
Strategy
Ranbaxy is focused on increasing the momentum in the generics business in its key markets through
organic and inorganic growth routes. Growth is well spread across geographies with focus on developed
and emerging markets. It is the Company's constant endeavour to provide a wide basket of generic and
innovator products, leveraging the unique Hybrid Business Model with Daiichi Sankyo. The Company will
also increasingly focus in high growth potential segments like Vaccines and Biogenerics. These new areas
will add significant depth to the existing product pipeline.
R&D
Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a
sustainable, long-term competitive advantage. The Company has a pool of over 1,200 R&D personnel
engaged in path-breaking research.
Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research
program in the late 70's, in support of its global ambitions. A first-of-its-kind world class R&D centre was
commissioned in 1994. Today, the Company has multi-disciplinary R&D centers at Gurgaon, in India,
with dedicated facilities for generics research and innovative research. The R&D environment reflects its
commitment to be a leader in the generics space offering value added formulations and development of
NDA/ANDAs, based on its Novel Drug Delivery System (NDDS) research capability. Ranbaxy's first
significant international success using the NDDS technology platform came in September 1999, when
the Company out-licensed its first once-a-day formulation to a multinational company.
In July 2010, Ranbaxy's New Drug Discovery Research (NDDR) was transferred to Daiichi Sankyo India
Pharma Private Limited as part of the strategy to strengthen the global Research and Development
structure of the Daiichi Sankyo Group. NDDR is now an integral part of Daiichi Sankyo Life Science
Research Center in India, based in Gurgaon.
However, Ranbaxy continued to independently develop the anti-malarial new drug, arterolane maleate
+ piperaquine phosphate that has been approved by the Indian Drug Regulator, Drug Controller General
of India (DCGI) for manufacturing and marketing in India. In April 2012, Ranbaxy launched India's first
new drug, SynriamTM, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults.
The company will also explore the further development of late stage programs developed by NDDR in
the last few years, including the development programs in the GSK collaboration. Within Ranbaxy, R&D
of Generics will now get a sharper focus, as the Company is increasingly working on more complex and
specialist areas
12. 12 | P a g e
Shree Agrasain College 2012
Worldwide Operations
Global Pharma Companies are experiencing an ever changing landscape ripe with challenges and
opportunities. In this challenging environment Ranbaxy is enhancing its reach leveraging its
competitive advantages to become a top global player.
Driven by innovation and speed to market we focus on delivering world-class generics at an
affordable price. Our unwavering determination to achieve excellence leads us to new global
benchmarks. Our people have consistently risen above all challenges maximized opportunities and
positioned Ranbaxy as a leader in the global generics space.
Ranbaxy's global footprint extends to 43 countries embracing different locales and cultures to form
a family of 50 nationalities with an intellectual pool of some of the best minds in the world.
Africa Asia Pacific CIS
Europe Global API Global Consumer Healthcare
India Latin America Middle East and Sri Lanka
North America
13. 13 | P a g e
Shree Agrasain College 2012
Products
Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and
markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active
Pharmaceuticals (API) and intermediates.
The Company remains focused on ascending the value chain in the marketing of pharmaceutical
substances and is determined to bring in increased revenues from dosage forms sales.
Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countries worldwide,
encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare
trends project that the chronic treatment segments will outpace the acute treatment segments, primarily
driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in
Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and
Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing
chronic and lifestyle disease segments.
Top 10 Molecules (2010)
• Valacyclovir
• Simvastatin
• Donepezil
• Atorvastatin & Combinations
• Co-amoxyclav & Combinations
• Ciprofloxacin & Combinations
• Ketorolac Tromethamine
• Imipenem+Cilastatin
• Ginseng+Vitamins
• Loratadine & Combinations
15. 15 | P a g e
Shree Agrasain College 2012
For selecting a target debt –equity mix, the firm analyses a number of factors. One such factor is leverage. The
capital structure decision involves a choice between risk and expected returns. The use of more and more debt
capital raises the risk factor of the firm’s earnings stream but it also tends to provide a higher expected rate of
return to the shareholders. In this chapter, we consider the various aspects of leverage and risks in planning the
capital structure of a firm.
The concept and nature of leverage:-
The term leverage is also used in business terminology. It describe the ability of a firm to used fixed cost
assets or funds to magnify the return to the shareholders, in other words, it implies that, other things
remaining, a relatively small changes in sales results in a large change in income(profit before interest & tax).it
may be mentioned that leverage may occur in a varying degrees. The higher the degree of leverage, the greater
is the risk. But at the same time, it also increased the possibility of higher rate of return to the shareholders.
The term “risk” implies the degree of uncertainty that the firm has to face in meeting fixed-payment obligation
(i.e. operating fixed costs and costs of pref. and debt capital).
Two types of leverage are used in business terminology viz.: (i) operating leverage arising out of fixed
operating cost, and (ii) financial leverage arising out of fixed financial charges. Operating leverage indicates the
degree of operating risk while financial leverage signifies the degree of financial risk of the firm. The combined
effect of operating and financial leverage provides a risk profile or the total risk of the firm. Before we take up
leverage for discussion it is important to discuss briefly various types of risk—business or operating risk and
financial risk.
Introduction
16. 16 | P a g e
Shree Agrasain College 2012
Various risks
Operating risks
This represents the variability in earnings before interest and taxes (EBIT) due to the risk inherent in the operation
of the firm. It is also called business risk. Variability in EBIT may be due in sales. Variability in sales depends on the
nature of the firm’s market, the industry and economy at large. Similarly, variability in EBIT also depends on the
variability of the operating cost of the firm. The various factors that contribute to the operating and business risk
are discussed below:-
(i) Variability in demand,
(ii) Variability in selling price,
(iii) Variability in input prices and firm’s capacity to adjust out prices accordingly,
(iv) Ability to develop new products,
(v) The extent of fixed costs in the total cost structure of the firm.
(vi) The asset structure of the firm.
Financial risk:-
Financial risk is associated with the financing decisions of the firm. This risk essentially refers to the use of debt
and prep, capital in the capital structure of the firm. Since the debt capital is usually cheaper than equity, the use
of debt increase the rate of return on equity as long as the rate of return on equity as long as the rate of return
exceeds the cost of debt capital. Financial risk an umbrella term for multiple types of risk associated with
financing, including financing transaction that include company loans in risk of default Risk is a term often
used to imply downside risk meaning the uncertainty of a return and the potential for financial loss. There are
various types of risk which are discussed below:-
(i) Asset-backed risk,
(ii) Credit risk,
(iii) Foreign investment risk,
(iv) Liquidity risk,
(v) Market risk,
(vi) Operational risks.’
Since financial risk is associated with debt or pref. capital, if no debt or pref. capital is used in the
capital structure of the firm, there is no financial risk. Thus, a firm that finances by equity only does not
face any financial risk.
17. 17 | P a g e
Shree Agrasain College 2012
Capital structure
In finance, capital structure refers to the way a corporation finances its assets through some
combination of equity, debt, or hybrid securities. A firm's capital structure is then the composition or
'structure' of its liabilities. For example, a firm that sells 20 billion in equity and 80 billion in debt is said
to be 20% equity-financed and 80% debt-financed. The firm's ratio of debt to total financing, 80% in this
example, is referred to as the firm's leverage. In reality, capital structure may be highly complex and
include dozens of sources. Gearing Ratio is the proportion of the capital employed of the firm which
come from outside of the business finance, e.g. by taking a short term loan etc.
A mix of a company's long-term debt, specific short-term debt, common equity and preferred equity.
The capital structure is how a firm finances its overall operations and growth by using different
sources of funds.
Debt comes in the form of bond issues or long-term notes payable, while equity is classified as
common stock, preferred stock or retained earnings. Short-term debt such as working capital
requirements is also considered to be part of the capital structure.
The Modigliani-Miller theorem, proposed by Franco Modigliani and Merton Miller, forms the basis for
modern thinking on capital structure, though it is generally viewed as a purely theoretical result since it
disregards many important factors in the capital structure decision. The theorem states that, in a perfect
market, how a firm is financed is irrelevant to its value. This result provides the base with which to
examine real world reasons why capital structure is relevant, that is, a company's value is affected by
the capital structure it employs. Some other reasons include bankruptcy costs, agency costs, taxes, and
information asymmetry. This analysis can then be extended to look at whether there is in fact an optimal
capital structure: the one which maximizes the value of the firm.
4,4
6,4
2,2
2,12
capital structure
EQUITY
DEBT
PREFERENCE
OTHER
18. 18 | P a g e
Shree Agrasain College 2012
Types of leverage
Operating leverage
Operating leverage is a measure of how sensitive net operating income is to percentage changes in sales.
Operating leverage acts as a multiplier. If operating leverage is high, a small percentage increase in sales can
produce a much larger percentage increase in net operating income. It is high near the breakeven point and
decreases as the sales and profit increase.
The degree of operating leverage (DOL) is a measure, at a given level of sales of how a percentage change in sales
volume will affect profits.
[Degree of operating leverage (DOL) = Contribution margin ÷ Net operating income]
This can also be computed as Total Contribution Margin over Operating Income:
Financial leverage
Financial leverage can be defined as the degree to which a company uses fixed-income securities, such as debt
and preferred equity. With a high degree of financial leverage come high interest payments. As a result, the
bottom-line earnings per share is negatively affected by interest payments. As interest payments increase as a
result of increased financial leverage, EPS is driven lower.
As mentioned previously, financial risk is the risk to the stockholders that is caused by an increase in debt and
preferred equities in a company's capital structure. As a company increases debt and preferred equities, interest
payments increase, reducing EPS. As a result, risk to stockholder return is increased. A company should keep its
optimal capital structure in mind when making financing decisions to ensure any increases in debt and preferred
equity increase the value of the company.
Degree of Financial Leverage
This measures the percentage change in earnings per share over the percentage change in EBIT. This is known as
"degree of financial leverage" (DFL). It is the measure of the sensitivity of EPS to changes in EBIT as a result of
changes in debt.
DFL =
𝑬𝑩𝑰𝑻
𝑬𝑩𝑰𝑻−𝑰𝒏𝒕𝒆𝒓𝒆𝒔𝒕
Or
19. 19 | P a g e
Shree Agrasain College 2012
Operating leverage and C-V-P analysis
1. The cost-volume - profit (CVP) analysis is a device to study the behavior of profit in response to changes in
volume, costs and price.
1. The break-even analysis - a popular form of the CVP analysis indicates the level of sales at which
revenues equal costs. The equilibrium point is called the break-even point.
In the CVP analysis, costs are separated into fixed and variable costs. Variable costs changes in direct
proportion to change in volume while fixed costs remain constant. The different between sales (selling
price) and variable costs (variable cost per unit is called contribution (contribution per unit. ) A firm should
generate sufficient contributions from the sale of its products to recover fixed costs and leave a
reasonable amount of profit. As the break-even sales, profit is defined to be zero; therefore, contribution
will be equal to fixed cost. If contribution per unit (vie, selling price minus variable cost per unit) and fixed
costs are known, the break-even point in units can be computed as follows:
Break - even point (in units) = Fix cost / Contribution per unit
The contribution ratio, also called P/V ratio , is equal to contribution ( contribution per unit ) divided by
sales ( selling price ) , Using contribution ,or P/V ratio, the breakeven point in rupees can be found as
follows;
Break even point ( in units ) = Fixed costs / Contribution Unit
The excess of actual or budget sales over the break even sales is called the margin of safety. It indicates
the extent to which sales may fall before the firm suffers a loss. An important concept in context of the
CVP analysis is the operating advantage. Operating advantage refers to the use of fixed costs in the
operation of a firm. And it accentuates fluctuations (increasing or decreases) in the firm operating profit
due to changes in sales. Thus the degree of operating advantage DOL may be defined as the percentage
change in operating profit (earnings before interests and taxes EBIT) on account of a change in sales:
DOL = (EBIT - Sales)
Alternatively, DOL can be measured as follows:
DOL = Contribution / EBIT
2. The CVP analysis is a very useful technique to reflect the effect of changes in volumes, costs and prices on
profits. The break - even point will be lowered and profit increased whenever fixed costs and /or variable
costs decrease or selling price increase. Profit will also increase when volume increase and other factors
remain constant.
20. 20 | P a g e
Shree Agrasain College 2012
The CVP analysis has the following advantages
(1) it is a simple device to understand accounting data.
(2) It is a useful diagnostic
(3) it provides basic information for further profit improvement studies.
(4) It is a useful method for considering the risk implication of alternative sections. It should be noted that the CVP
analysis is based on a number of assumptions that may not be realistic at times. Therefore, it should be used with
caution.
The use of the CVP analysis may be limited because of the following reasons
(1) it is difficult to separate costs into fixed and variable components.
(2) Fixed costs may not remain constant over the entire range of volume.
(3) Selling price and variable cost per unit may not remain constant.
(4) It is difficult to use the CVP analysis for a multi product firm.
(5) It is a short run concept.
(6) It is a static tool.
profit 40
Area 30 profit ( Rs. ‘000s)
Break even point 20
Sales(Rs. ‘000s) 10
50 100 150 200
TFC 20
(‘000) 30
40 Profit-Volume Graph
50
Loss area
21. 21 | P a g e
Shree Agrasain College 2012
Breakeven chart
A breakeven chart is a strategic tool used to plot the financial revenue of a business unit against time or sales to
determine the point when sales output is equal to revenue generated. This is recognised as the breakeven point.
The information used to determine and analyze the breakeven point includes fixed, variable and total costs and
the associated sales revenues. They are defined as:
Fixed costs: costs that do not vary in relation to the level of sales output, for example rent.
Variable costs: costs that vary in proportion to the level of sales output, for example materials.
Total costs: the sum of all costs, including fixed and variable.
Associated sales revenues: the total revenue made by the company from sales. It can be derived by
multiplying price by output.
The analysis of a breakeven chart considers whether a venture runs at a profit or a loss. A sale above the
breakeven point indicates continued and profitable growth. The principle of break-even theory is that during the
early stages of a business venture, total costs, both fixed and variable, exceed sales. As output increases, sales
begin to rise faster than costs and, eventually, they become equal (breakeven point). If sales continue to rise and
exceed total costs, the business achieves profitability.
The tool assumes that all the goods which are produced will be sold and that costs, namely the price, will remain
constant. Likewise, it also relies on the capacity in terms of output to remain unchanged.
Breakeven charts are universally applied to simply and graphically illustrate and forecast a company's projected
revenue, and to calculate the time for profitability to be reached. It is used by financial and marketing strategists
to predict the effect that changes in price will have on the percentage change in sales over time. It is also a useful
tool to analyze the relationship between fixed and variable costs and to predict the effect on profitability of
changes to those costs.
22. 22 | P a g e
Shree Agrasain College 2012
Certain assumption need to be made for the purpose of construction of a BEC. They are:
Fixed costs tend to remain constant. In other word, there is no change in cost factor, such as,
change in property tax rate, insurance rate, salaries of staff, etc. or in management policy.
Prices of variable costs factors, i.e. wage rates, price of materials, surplice, services, etc. remain
unchanged so that variable costs are truly variable.
Semi- variable costs can be segregated into variable and fixed elements.
Product specification and methods of manufacturing and selling do not undergo a change.
Operating efficiency does not increase or decrease.
There is no change in pricing policy due to change in volume, competition, etc.
The number of units of sales coincides with this unit produced so that there is no closing or
opening stock. Alternatively, the change in opening and cl. Stock are insignificant and are valued
at the same prices, or variable costs.
Product-mix remains unchanged.
The BEP can be determined from a BEC or can be calculated as follows :
(i) BEP (units) =total fixed costs / unit contribution
(ii) BEP (sales value) :
(a) TFC / unit contribution * sppu
(b) TFC / unit contribution * total sales value
EBIT/EPS Analysis
EBIT - Earnings before Interest and Taxes. Accountants like to use the term Net Operating Income for this income
statement item, but finance people usually refer to it as EBIT (pronounced as it is spelled - E, B, I, T). Either way,
on an income statement, it is the amount of income that a company has after subtracting operating expenses
from sales (hence the term net operating income). Another way of looking at it is that this is the income that the
company has before subtracting interest and taxes (hence, EBIT).
EAT - Earnings After Taxes. Accountants call this Net Income or Net Profit After Taxes, but finance people usually
refer to it as EAT (pronounced E, A, T).
EPS - Earnings per Share. This is the amount of income that the common stockholders are entitled to receive (per
share of stock owned). This income may be paid out in the form of dividends, retained and reinvested by the
company, or a combination of both. (It is pronounced E, P, and S).
I need to raise additional money by issuing either debt, preferred stock, or common stock. Which alternative will
allow me to have the highest earnings per share?
23. 23 | P a g e
Shree Agrasain College 2012
This question calls for an EBIT/EPS analysis. The EBIT-EPS analysis, as a method to study the effect of leverage,
essentially involves the comparison of alternative methods of financing under various assumptions of EBIT. A firm
has the choice to raise funds for financing its investment proposals from different sources in different
proportions. For instance, it can (i) exclusively use equity capital (ii) exclusively use debt, (iii) exclusively use
preference capital, (iv) use a combination of (i) and (ii) in different proportions; (v) a combination of (i), (ii) and (iii)
in different proportions, (vi) a combination of (i) and (iii) in different proportions, and so on. The choice of the
combination of the various sources would be one which, given the level of earnings before interest and taxes,
would ensure the largest EPS
The graph showing highest EBIT &EPS under optimum combination of capitals.
24. 24 | P a g e
Shree Agrasain College 2012
Capital structure
The data are extracted from the Standalone Balance Sheet Of the given
years
Ranbaxy Laboratories (Rupees in millions)
SOURCES OF
FUNDS
31 Dec
2011
31 Dec
2010
31 Dec
2009
31Dec
2008
31 Dec
2007
Share Sapital
Preference capital
Reserves and
surplus
Loan funds
-Secured Loans
-Unsecured Loans
2,110.00
Nil
38,242.71
3,373.41
41,533.88
2,105.20
Nil
53,876.00
2,369.38
40,978.67
2,102.09
Nil
39,573.29
2,186.62
34,108.60
2,101.85
Nil
39,104.03
2,109.35
41,005.04
1,865.35
Nil
26,156.77
4,102.55
37,313.17
Total 85260.00 99329.25 77970.6 84320.27 69437.84
In the above data it is seen that every year company increases it share capital capital
upto amounting 2110 million , reserve and surplus increases upto year 2010
amounting Rs. 53,876.00 million but in year 2011 its decreases to 38,242.71 million,
but in case of loan funds its increases and decreases as per companies needs. The
various chart and graph showing trends of capital structure:-
25. 25 | P a g e
Shree Agrasain College 2012
Capital structure for the year 2011
above data are shown in percentage mix of capital funds .
From the above data, it is clearly seen that company has small percentage of equity share
capital and secured loan in its capital structure and company belief in large amount of
unsecured loan in its capital structure to finance the organisation but company has also
having a greater percentage of reserve & surplus which ultimately keeps company strong
in opting any financial decision regarding any investment which is made through its
internal funds.
Share Capital
Preference
Share
Reserve and
Surplus
Secured loan
Unsecured
loan
Capital structure for the year 2011 2,48% 0 44,85% 3,96% 48,71%
2,48%
0
44,85%
3,96%
48,71%
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
Mixofcapitalstructure
Capital structure for the year 2011
26. 26 | P a g e
Shree Agrasain College 2012
Chart showing flow of capital funds.
0,00
10000,00
20000,00
30000,00
40000,00
50000,00
60000,00
31-12-2007 31-12-2008 31-12-2009 31-12-2010 31-12-2011
Share Sapital
Preference capital
Reserves and surplus
Secured Loans
Unecured Loans
27. 27 | P a g e
Shree Agrasain College 2012
Trend of Total Fund in last five year
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
year 2007
year 2008
year 2009
year 2010
year 2011
69437,84
84320,27
77970,6
99329,25
85260
Títulodeleje
year 2007 year 2008 year 2009 year 2010 year 2011
Total Funds 69437,84 84320,27 77970,6 99329,25 85260
Total Funds
28. 28 | P a g e
Shree Agrasain College 2012
Table Showing Profit before Tax for Last Five Years
Particulars 31 dec
2011
31 dec
2010
31 dec
2009
31 dec
2008
31 dec
2007
Sales
(Less) Variable Cost—Material
Contribution
(Less) Fixed Cost
Personnel Exp.
Operating & Other Exp.
Depreciation
EBIT
(Less) Interest
Profit before Exceptional Items
(Add/ Less) Exceptional Items
Profit before Tax / EBT
80363.82
23861.06
66738.84
21709.34
52381.87
20480.28
46817.70
18792.58
47783.22
17813.13
56502.76
8647.87
31842.33
2740.83
45029.5
7761.38
14712.20
2283.53
31901.59
7284.04
13614.82
1482.03
28025.12
4730.25
18743.73
1544.69
29970.09
4216.14
15888.32
1187.31
13271.73
6035.58
20272.39
541.94
9520.7
394.66
3006.45
1458.28
8678.32
934.26
7236.15
37722.85
19730.45
4078.00
9126.04
(1493.13)
1548.17
17738.98
7744.06
Nil
(30486.7) 15652.45 10619.17 (16190.81) 7744.06
29. 29 | P a g e
Shree Agrasain College 2012
Table showing DOL, DFL, & DCL of Last Five Years
Particulars 31-Dec
2011
31-Dec
2010
31-Dec
2009
31-Dec
2008
31-dec
2007
Contribution
EBIT
EBT
(millions)
56502.76
13271.73
(30486.7)
(millions)
45029.5
20272.39
15652.45
(millions)
31901.59
9520.7
10619.17
(millions)
28025.12
3006.45
(16190.81)
(millions)
29970.09
8678.32
7744.06
DOL =
𝑪𝑶𝑵𝑻𝑹𝑰𝑩𝑼𝑻𝑰𝑶𝑵
𝑬𝑩𝑰𝑻
DFL =
𝑬𝑩𝑰𝑻
𝑬𝑩𝑻
DCL =
𝑪𝑶𝑵𝑻𝑹𝑰𝑩𝑼𝑻𝑰𝑶𝑵
𝑬𝑩𝑻
4.257
(0.435)
(1.853)
2.221
1.295
2.87
3.357
0.897
3.005
9.322
(0.186)
(1.731)
3.453
1.121
3.871
30. 30 | P a g e
Shree Agrasain College 2012
Graph showing trend of DOL, DFL & DCL
3,453
9,322
3,357
2,221
4,257
1,121
-0,186
0,897
1,295
-0,435
3,871
-1,731
3,005
2,87
-1,853
0
1
2
3
4
5
6
7
8
9
10
31-03-2007 31-03-2008 31-03-2009 31-03-2010 31-03-2011
DCL
DFL
DOL
31. 31 | P a g e
Shree Agrasain College 2012
SOURCES OF FUNDS
Particulars Rs. Amount
(in millions)
SOURCES OF FUNDS
Shareholders’ Funds
Share Capital
Reserves and Surplus
Loan Funds
Secured Loans
1,035.6
65,769.7
505.3
sources of funds (in millions)
Share Capital
Reserve & Surplus
Secured loans
32. 32 | P a g e
Shree Agrasain College 2012
Table showing EBIT & EBT
particulars Details Rs.
(in millions)
Amount Rs.
(in millions)
Sales
(less) Material Cost (variable)
Contribution
(less) Fixed Cost
Personnel Cost
Operating and Other Expenses
Operating and Other Expenses
Research and Development Expenditure
Depreciation / Amortisation / Impairment
EBIT
(Less) Interest
EBT
32,988.7
8,969.3
8,969.3
2,140.6
5,340.4
1,355.9
642.3
24019.4
18448.5
5570.9
5.9
5565
Sun Pharmaceutical Industries
DOL =
𝑪𝑶𝑵𝑻𝑹𝑰𝑩𝑼𝑻𝑰𝑶𝑵
𝑬𝑩𝑰𝑻
DFL =
𝑬𝑩𝑰𝑻
𝑬𝑩𝑻
DCL =
𝑪𝑶𝑵𝑻𝑹𝑰𝑩𝑼𝑻𝑰𝑶𝑵
𝑬𝑩𝑻
4.312
1.001
4.316
33. 33 | P a g e
Shree Agrasain College 2012
Comparison of DOL, DFL, & DCL of Ranbaxy Laboratories &
Sun Pharmaceutical Industries.
4,22
4,23
4,24
4,25
4,26
4,27
4,28
4,29
4,3
4,31
4,32
RANBAXY LABORATORIES
LTD
Sun Pharmaceutical
Industries Limited
4,257
4,312
DOL
RANBAXY LABORATORIES LTD
Sun Pharmaceutical Industries Limited
34. 34 | P a g e
Shree Agrasain College 2012
-0,6
-0,4
-0,2
0
0,2
0,4
0,6
0,8
1
1,2
RANBAXY LABORATORIES
LTD
Sun Pharmaceutical
Industries Limited
1,001
DFL
RANBAXY LABORATORIES LTD
Sun Pharmaceutical Industries Limited
-100% -50% 0% 50% 100%
Ranbaxy Laboratories Limited
Sun Pharmaceutical Industries
Limited
-1,853
4,316
DCL
Ranbaxy Laboratories Limited
Sun Pharmaceutical Industries Limited
35. 35 | P a g e
Shree Agrasain College 2012
Particulars Ranbaxy
Laboratories
Sun
Pharmaceutical
Industries
Sales
EBIT
Capital Employed
80363.82
13271.73
80,753.65
32988.7
5570.9
68,595.7
Return on capital employed =
𝑬𝑩𝑰𝑻
𝑪𝒂𝒑𝒊𝒕𝒂𝒍 𝑬𝒎𝒑𝒍𝒐𝒚𝒆𝒅
× 𝟏𝟎𝟎 = 16.43% 8.12%
………………………………………………………………………………………
Profit Margin =
𝑬𝑩𝑰𝑻
𝑺𝒂𝒍𝒆𝒔
× 𝟏𝟎𝟎 16.51% 16.88%
……………………………………………………………………………………………
Assets Leverage =
𝑺𝒂𝒍𝒆𝒔
𝑪𝒂𝒑𝒊𝒕𝒂𝒍 𝑬𝒎𝒑𝒍𝒐𝒚𝒆𝒅
0.995 0.481
36. 36 | P a g e
Shree Agrasain College 2012
Comparison of EPS of Ranbaxy Laboratories &
Sun Pharmaceutical Industries
Years EPS EPS
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
-72.32
27.28
13.61
-24.85
16.56
10.21
5.69
28.38
42.84
33.62
13.36
43.39
61.09
48.96
32.52
24.83
16.48
25.84
24.83
36.33
37. 37 | P a g e
Shree Agrasain College 2012
Graph showing trend of EPS in last 10 years
Ranbaxy Laboratories & Sun Pharmaceutical
Industries
-80
-60
-40
-20
0
20
40
60
80
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Ranbaxy Laboratories
Sun Pharmaceutical Industries
38. 38 | P a g e
Shree Agrasain College 2012
Graph showing trend of Sales of Ranbaxy Laboratories:
0
10000
20000
30000
40000
50000
60000
70000
80000
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Sales (in millions)
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
40. 40 | P a g e
Shree Agrasain College 2012
Recomrere
Regarding Capital Structure :
As we can easily see that company RANBAXY LABORATORIES , has huge capital funds
available but these fund are available for operating business is mainly acquired from
loan funds i.e. from unsecured loan from external world as compared to Equity capital
and secured loan. Company also has huge amount of reserve & surplus. Having huge
amount of Unsecured loan in capital funds reflects high much burden of fixed financial
charges i.e. Interest. From the above given data’s, it is clearly seen that company has
small percentage of equity share capital and secured loan in its capital structure and
company belief in large amount of unsecured loan in its capital structure to finance the
organisation but company has also having a greater percentage of reserve & surplus
which ultimately keeps company strong in opting any financial decision regarding any
investment which is made through its internal funds.
Here the mix of capital funds is not Adequate, and company doesn’t have any
preference share capital which may can affect the Earning Per Share (EPS) of RANBAXY
LABORATORIES.
The company should go for better mix of capital funds. Company should raise its capital
funds and cut down its Unsecured loan funds but its not need to raise preference share
capital being of non-tax advantage.
Recommendation
41. 41 | P a g e
Shree Agrasain College 2012
Need to Raise Funds
(Capital budgeting decision)
Capital Structure Decisions
Debt-Equity mix
Financial Risk Trade off NEDC Risk
Market value of firm’s
42. 42 | P a g e
Shree Agrasain College 2012
Regarding Leverage:
In the income statement of RANBAXY LABORATORIES, company has low lavel of
variable costs but company has greater Fixed Cost which ultimately turns to high
Operating Leverage
As shown above. High much fixed costs reflects high level of Break Even Point which
means company have to sale more units of products.
In the income statement of company there is an exceptional item which may reduce
the Profit before Tax ultimately reduce the financial leverage.
As a matter of prudent financial policy, a low operating leverage followed by a high
financial leverage is considered to be an Ideal situation for the maximization of the
company’s profit with minimum risk but RANBAXY LABORATORIES is running on inverse
situation having low profit with greater risks.
43. 43 | P a g e
Shree Agrasain College 2012
As Eugene F. Brigham explained in Fundamentals of Financial Management, "The optimal capital
structure is the one that strikes a balance between risk and return and thereby maximizes the price of
the stock and simultaneously minimizes the cost of capital."
The primary advantage of debt financing is that it allows the founders to retain ownership and control
of the company. In contrast to equity financing, the entrepreneurs are able to make key strategic
decisions and also to keep and reinvest more company profits. Another advantage of debt financing is
that it provides small business owners with a greater degree of financial freedom than equity financing.
Debt obligations are limited to the loan repayment period, after which the lender has no further claim
on the business, whereas equity investors' claim does not end until their stock is sold. Debt financing is
also easy to administer, as it generally lacks the complex reporting requirements that accompany some
forms of equity financing. Finally, debt financing tends to be less expensive for small businesses over the
long term, though more expensive over the short term, than equity financing.
The main advantage of equity financing for small businesses, which are likely to struggle with cash flow
initially, is that there is no obligation to repay the money. Equity financing is also more likely to be
available to concept and early stage businesses than debt financing. Equity investors primarily seek
growth opportunities, so they are often willing to take a chance on a good idea. But debt financiers
primarily seek security, so they usually require the business to have some sort of track record before
they will consider making a loan. Another advantage of equity financing is that investors often prove to
be good sources of advice and contacts for small business owners.
Leverage is both one of the biggest advantages and disadvantages in Forex. Depending on the broker
you’re using, leverage can be up to 200:1 or even 400:1. A 400:1 leverage means that you can trade up
to 400 times the money you have on your account. So, for each Rs. 1000 you have on your account, you
can trade up to Rs. 400.000.
ADVANTAGE
44. 44 | P a g e
Shree Agrasain College 2012
Advantages:
Considering you can trade up to 200 times or even 400 times your money, one of the advantages is that
you can make huge profits even if you don’t have much money on your account. Considering for
example the maximum 400:1 leverage, with just 0.25% of movement in your direction, you can double
your account.
So, when you’re right about a trade, leverage really pays off. No other market in the world offers so
much leverage, and that’s why Forex has been attracting many traders
you're probably all too familiar with how leverage works and the benefits it can have on your trading
success. Prolific traders across the world are using leverage to gear up their potential winnings, and to
boost their incomes beyond capital restraints, maximising their trading advantage with the help of their
brokers and financing partners. Indeed, high-risk investment funds are leveraging billions in principal
capital to deliver a return for investors, and with careful and rigorous management of risk leverage can
add significant value to your trading endeavours.
45. 45 | P a g e
Shree Agrasain College 2012
Very much complex data: The data in Annual Report of RANBAXY LABORATORIES
is very much complex which raise various difficulties in making projects.
Lack of adequate data: data in the annual report is lack of some data which
reflects inadequate info:
Comparative study required : leverage are useful in judging the efficiency of the
business only when they are compared with past results of the business. However,
such a comparison only provide glimpse of the past performance and forecasts for
future may not prove correct since several other factors like market conditions,
management policies, etc. may affect the future operations.
Personal bias: leverage are only means of financial analysis and not an end in itself.
leverage have to interpret and different people may interpret the same ratio in
different way.
Incomparable: Not only industries differ in their nature, but also the firms of
the similar business widely differ in their size and accounting procedures etc.
It makes comparison of ratios difficult and misleading.
LIMITATION
46. 46 | P a g e
Shree Agrasain College 2012
In order to survive in the long run, every company needs to plan about capital structure and very
decide the combination of sources of funds after observing the factors affecting capital
structures. With the help of strong capital structure planning, companies can strengthen their
balance sheets. If you select the right capital structure then it will also increase your company’s
power to face the losses and changes in financial market. Effective capital structure also helps
companies to reduce the overall risk of the companies.
Before making capital structure, companies ‘managers must analyze their profitability position and
find out that either the demand of debt investor is high then the expectation of shareholders
regarding dividend or not. Proper planning of capital structure also helps companies to enlarge their
area for getting funds as well as creates the mobility of sources of the funds. Companies should also
include the different and maximum alternatives in their capital structure.
Concepts of financial and operating leverages are important for evaluating business and financial
risk of a firm. Operating leverage refers to the use of fixed costs in operations and it is related to the
firm's production processes. The greater the operat-ing leverage the higher is the risk in operations.
At the same time, a high degree of operating leverage causes profits to rise rapidly after the break-
even point is reached. Financial leverage refers to the use of debt in financing non-current assets. If
the return on assets exceeds the cost of debt, the leverage is successful i.e., it improves returns on
equity. While this being so, a high financial leverage magnifies financial risk. At some degree of
financial leverage the cost of debt rises because of increased risk with the higher fixed charges.
When this happens, riskiness of the firm also increases in the eyes of equity investors who start
expecting a higher return to compensate for the increased risk burden. Financial leverage and
operating leverage are related with each other. Both have similar effects on profits. A greater use of
either i.e., operating or financial leverage leads to following results:
a) The break-even point is raised
b) The impact of change in the level of sales on profits is magnified
The impact of change in the level of sales on profits is magnified. Operating and financial leverages
have reinforcing effects. Operating, or first-stage leverage affects earnings before interest and taxes
(i.e., net operating income) while financial, or second-stage leverage affects earnings after interest
and taxes (i.e., net income available to equity shareholders).
Conclusion
47. 47 | P a g e
Shree Agrasain College 2012
Web Sites
www.Google.Com
www.wikipedia.com
www.moneycontrol.com
www.NSEINDIA.com
www.indiabulls.com
book references
Financial Policy and Management Accounting by B. Banarjee
An Introduction to Financial Management by Majumdar-Ali-Nisha
Financial Management by Robi M kishore
From College:
Prof. Lal Saheb Verma
Prof. Nibir Goswami
S.P
A. S
Bibliography